Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2007-05-04
2010-12-28
Ton, Thaian N (Department: 1632)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100, C536S023200
Reexamination Certificate
active
07858369
ABSTRACT:
Transgenic non-human animals that express the γ3 subunit of PRKAG are described, as well as methods of using the transgenic non-human animals as models for improving treatment, prevention, or diagnosis of diseases related to energy metabolism, including obesity, dyslipidemia, insulin resistance syndrome, and type 2 diabetes.
REFERENCES:
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5846720 (1998-12-01), Foulkes et al.
patent: 7208305 (2007-04-01), Hjälm
patent: 2002/0142310 (2002-10-01), Andersson et al.
patent: 2005/0155091 (2005-07-01), Svensson
patent: 2007/0199081 (2007-08-01), Andersson et al.
patent: WO 97/25341 (1997-07-01), None
patent: WO 01/20003 (2001-03-01), None
patent: WO 01/77305 (2001-10-01), None
Subramaniam et al. J. of Biol. Chem, 266(36): 24613-24620, 1991.
GenBank Accession No. AB022017 dated Jan. 8, 1999, 2 pages.
GenBank Accession No. AAH48980 dated Apr. 22, 2003, 2 pages.
GenBank Accession No. AC009974 dated Feb. 11, 2004, 120 pages.
GenBank Accession No. AF214519 dated Jun. 3, 2000, 2 pages.
GenBank Accession No. AF249977 dated Jun. 28, 2001, 1 page.
Cameron, “Recent Advances in Transgenic Technology,”Mol. Biotechnol., 1997, 7:253-265.
Cheung et al., “Characterization of AMP-activated protein kinase γ-subunit isoforms and their role in AMP binding,”Biochem. J., 2000, 346:659-669.
Collins, “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences,”Proc. Natl. Acad. Sci. USA, 2002, 99(26):16899-16903.
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens,”Proc. Natl. Acad. Sci. USA, 1983, 80:2026-2030.
Davies et al., “Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay,”Eur. J. Biochem., 1989, 186:123-128.
Engh and Bossemeyer, “The Protein Kinase Activity Modulation Sites: Mechanisms for Cellular Regulation—Targets for Therapeutic Intervention,”Advan. Enzyme Regul., 2001, 41:121-149.
Foretz et al., “AMP-activated Protein Kinase Inhibits the Glucose-activated Expression of Fatty Acid Synthase Gene in Rat Hepatocytes,”J. Biol. Chem., 1998, 273(24):14767-14771.
Goodyear, “AMP-Activated Protein Kinase: A Critical Signaling Intermediary for Exercise-Stimulated Glucose Transport?”Exerc. Sport Sci. Rev., 2000, 28:113-116.
Gros et al., “Insulin Production by Engineered Muscle Cells,”Hum. Gene Ther., 1999, 10(7):1207-1217.
Hardie and Carling, “The AMP-activated protein kinase. Fuel gauge of the mammalian cell?”Eur. J. Biochem., 1997, 246:259-273.
Hardie et al., “The AMP-Activated/SNF1 Protein Kinase Subfamily: Metabolic Sensors of the Eukaryotic Cell?”Annu. Rev. Biochem., 1998, 67:821-855.
Hardie and Hawley, “AMP-activated protein kinase: the energy charge hypothesis revisited,”BioEssays, 2001, 23:1112-1119.
Hayashi et al., “Evidence for 5′ AMP-Activated Protein Kinase Mediation of the Effect of Muscle Contraction on Glucose Transport,”Diabetes, 1998, 47:1369-1373.
Hochepied et al., “Breaking the Species Barrier: Derivation of Germline-Competent Embryonic Stem Cells fromMus spretusX C57BL/6 Hybrids,”Stem Cells, 2004, 22:441-447.
Holmes et al., “Chronic activation of 5′-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle,”J. Appl. Physiol., 1999, 87(5):1990-1995.
Houdebine, “Production of pharmaceutical proteins from transgenic animals,”J. Biotechnol., 1994, 34:269-287.
Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,”Science, 1989, 246:1275-1281.
Kappel et al., “Regulating gene expression in transgenic animals,”Curr. Opin. Biotechnol., 1992, 3:548-553.
Kemp et al., “Dealing with energy demand: the AMP-activated protein kinase,”Trends Biochem. Sci., 1999, 24:22-25.
Köhler and Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature, 1975, 256:495-497.
Kozbor and Roder, “The production of monoclonal antibodies from human lymphocytes,” Immunology Today, 1983, 4(3):72-79.
Lo, “Transformation by Iontophoretic Microinjection of DNA: Multiple Integrations Without Tandem Insertions,”Mol. Cell. Biol., 1983, 3:1803.
Lochhead et al., “5-Aminoimidazole-4-Carboxamide Riboside Mimics the Effects of Insulin on the Expression of the 2 Key Gluconeogenic Genes PEPCK and Glucose-6-Phosphatase,”Diabetes, 2000, 49:896-903.
Michell et al., “Isoform-specific Purification and Substrate Specificity of the 5′-AMP-activated Protein Kinase,”J. Biol. Chem., 1996, 271(45):28445-28450.
Merrill et al., “AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle,”Am. J. Physiol., 1997, 273:E1107-E1112.
Milan et al., “A Mutation inPRKAG3Associated with Excess Glycogen Content in Pig Skeletal Muscle,”Science, 2000, 288:1248-1251.
Mullins and Mullins, “Transgenesis in Nonmurine Species,”Hypertension, 1993, 22:630-633.
Mullins and Mullins, “Perspectives Series: Molecular Medicine in Genetically Engineered Animals,”J. Clin. Invest., 1996, 98(11):S37-S40.
Niemann, “Transgenic farm animals get off the ground,”Trans. Res., 1998, 7:73-75.
Rülicke et al., “Germ Line Transformation of Mammals by Pronuclear Microinjection,”Exp. Physiol., 2000, 85(6):589-601.
Schoonjans et al., “Improved Generation of Germline-Competent Embryonic Stem Cell Lines from Inbred Mouse Strains,”Stem Cells, 2003, 21:90-97.
Sigmund, “Viewpoint: Are Studies in Genetically Altered Mice Out of Control?”Arterioscler. Thromb. Vasc. Biol., 2000, 20:1425-1429.
Smith, “Gene transfer in higher animals: theoretical considerations and key concepts,”J. Biotech., 2002, 99:1-22.
Thompson et al., “Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targeting in Embryonic Stem Cells,”Cell, 1989, 56:313-321.
Van der Putten et al., “Efficient insertion of genes into the mouse germ line via retroviral vectors,”Proc. Natl. Acad. Sci. USA, 1985, 82:6148-6152.
Wakayama et al., “Full-term development of mice from enucleated oocytes injected with cumulus cell nuclei,”Nature, 1998, 394:369-374.
Wall, “Transgenic Livestock: Progress and Prospects for the Future,”Theriogenology, 1996, 45:57-68.
Wilmut et al., “Viable offspring derived from fetal and adult mammalian cells,”Nature, 1997, 385(6619):810-813.
Winder and Hardie, “AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes,”Am. J. Physiol., 1999, 277:E1-E10.
Wolf et al., “Transgenic Technology in Farm Animals. Progress and Perspectives,”Exp. Physiol., 2000, 85(6):615-625.
Zhou et al., “Role of AMP-activated protein kinase in mechanism of metformin action,”J. Clin. Invest., 2001, 108(8):1167-1174.
Andersson Leif
Marklund Stefan
Arexis AB
Fish & Richardson P.C.
Ton Thaian N
LandOfFree
Expression constructs expressing Prkag3 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Expression constructs expressing Prkag3, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression constructs expressing Prkag3 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4202341